Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Activity of Regorafenib in Combination With Modified Gemcitabine - Oxaliplatin Chemotherapy (mGEMOX) in Patients With Advanced Biliary Tract Cancer (BTC): A Phase Ib-II Trial (BREGO)

Next Previous
Trial Profile

Activity of Regorafenib in Combination With Modified Gemcitabine - Oxaliplatin Chemotherapy (mGEMOX) in Patients With Advanced Biliary Tract Cancer (BTC): A Phase Ib-II Trial (BREGO)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Regorafenib (Primary) ; Gemcitabine; Oxaliplatin
  • Indications Adenocarcinoma; Biliary cancer; Gallbladder cancer
  • Focus Adverse reactions
  • Acronyms BREGO

    • Most Recent Events

    • 07 Jan 2020 Status changed from recruiting to completed.
    • 05 Jun 2018 Results of phase 1b (n=20) assessing recommended phase II dose (RP2D) of regorafenib combined with mGEMOX as first-line therapy of aBTC, were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 20 Jan 2018 Results of phase Ib part of this study (n=22) presented at the 2018 Gastrointestinal Cancers Symposium.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top